Modern service propels Wuxi’s economic growth

2018年08月17日 15:28:02 | 来源:ourjiangsu.com

字号变大| 字号变小


  The city of Wuxi in east Chinas Jiangsu province saw the added value of its modern service industry make up more than 50% of the total in the first half of this year.

  Since the beginning of this year, Wuxi has actively implemented the three-year action plan for quality improvement and efficiency improvement in the modern service industry and related supporting policies to promote the service industry towards specialized and high-end development.

  A biologically-based alternative HIV treatment developed in Taiwan and manufactured in Wuxi city won the approval from the U.S. Food and Drug Administration last March, becoming the first such made-in-China drug to receive such approval.

  Ibalizumab-uiyk, which also goes by the name of Trogarzo, is a new option for people who have tried more conventional drugs without success to treat the virus that causes AIDS due to factors like resistance to those drugs, according to Taiwan-based TaiMed Biologics, which developed the drug and is producing it on the Chinese mainland with partner Wuxi Biologics.

  Trogarzo is the first drug in a new class of anti-retroviral medications that can provide significant benefit to patients who have run out of HIV treatment options.

  Efficacy of Trogarzo was demonstrated in a single arm, multicenter clinical trial of heavily treatment-experienced HIV-infected subjects with multidrug resistant HIV-1.

  With the reform of the review and approving system for drug approval in China and the related supporting policies, this innovative drug is also actively planning to be supplied to the home market so as to benefit more domestic patients.

  Wuxi Biologics is the world's leading provider of biologics services, providing customers with a one-stop shop for biomedical concepts from concept to production.

  Its parent company WuXi App Tec chose Wuxi for its destination of investment for its fine local resource environment from the enrollment of employees to the customs clearance, from factory lease to financial services, thanks to the government's all-round promotion.

  Currently, 11% of WuXi App Tec’s biomedical projects around the world are researched and developed here. In the future, App Tec's global headquarters will also be located in Wuxi to become one of the world's largest integrated centers for biopharmaceutical research, development and production services.

  Based on local characteristics, Wuxi has built 18 provincial-level modern service industry clusters with more than 26,000 enterprises. Last year, the city posted operating revenue of 384.2 billion yuan.

  In the future, Wuxi will continue to rely on its location advantages to accelerate industrial transformation, make full use of platform policy pilots such as cross-border e-commerce comprehensive test zones and national cultural export bases, and accelerate the establishment of a regional "service highland" in the Yangtze River Delta.

(Source: ourjiangsu.com)

layer
快乐分享